Clinical Trial Update: Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 update on repeat ascending doses of GSK2018682 in healthy volunteers, with relapsing-remitting multiple sclerosis listed as the condition.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GSK2018682 (GSK2018682)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 1 | Status: COMPLETED